GlassScriptPhysician profile
Sarah E Scullion
NPI 1922624725
$5,963.19
in general payments reported to CMS, 2019-2025
37 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $510 · 2022: $3,113 · 2023: $2,150 · 2024: $37.73 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,340.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $840.90 | 2021-2023 | Fasenra, Tezspire, Farxiga |
| Glaxosmithkline, LLC. | $533.19 | 2021-2024 | Trelegy Ellipta, Nucala, Shingrix |
| Grifols USA, LLC | $520.61 | 2022-2023 | Prolastin-C Liquid, Xembify |
| Amgen INC. | $491.17 | 2021-2023 | Tezspire, Otezla, Repatha |
| Novo Nordisk INC | $457.27 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $445.89 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $398.46 | 2022-2023 | Dupixent |
| Pfizer INC. | $298.84 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $278.99 | 2021-2023 | Hyqvia, Cuvitru |
| Otsuka America Pharmaceutical, INC. | $195.39 | 2022-2023 | Rexulti |
| Csl Behring | $176.12 | 2022-2023 | Hizentra |
| Genzyme Corporation | $137.10 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $124.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.87 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Biocryst US Sales Co., LLC | $119.12 | 2022-2023 | Orladeyo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $107.34 | 2023-2025 | Rexulti |
| Alk-Abello, INC | $67.19 | 2022 | |
| Kaleo, INC. | $65.97 | 2021-2022 | |
| Lilly USA, LLC | $54.70 | 2021-2022 | |
| Exact Sciences Corporation | $52.25 | 2023 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $52.25 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.24 | 2022-2023 | Xifaxan |
| Mylan Specialty L.P. | $50.93 | 2021-2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $49.26 | 2022 | |
| Vanda Pharmaceuticals INC. | $45.65 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $43.10 | 2022 | |
| Amarin Pharma, INC. | $32.85 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.94 | 2021 | |
| Bio Products Laboratory USA, INC. | $19.72 | 2022 | |
| Pharming Healthcare, INC. | $18.52 | 2023 | Ruconest |
| Daiichi Sankyo INC. | $16.11 | 2022 | |
| Horizon Therapeutics Plc | $15.75 | 2022 | |
| Astellas Pharma US INC | $14.96 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.85 | 2022 | |
| Covis Pharma Gmbh | $12.74 | 2022 | |
| Merck Sharp & Dohme LLC | $11.96 | 2021 | |
| Kerecis Limited | $8.00 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Scullion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.